Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Oncogene. 2008 Apr 14;27(34):4702–4711. doi: 10.1038/onc.2008.109

Figure 1.

Figure 1

BIBW2992 effectively inhibits anchorage-independent proliferation of NIH-3T3 cells ectopically expressing EGFR mutants. (a) NIH-3T3 cells expressing wild-type or mutant EGFR constructs were treated with the indicated concentrations of BIBW2992 or erlotinib and suspended in soft agar. Values shown are averages of triplicate samples normalized to absence of drug treatment; error bars represent s.d. Expression of mutant EGFR was confirmed by immunoblotting (data not shown). wt + EGF, wild-type EGFR-expressing NIH-3T3 cells supplemented with 100 ng/ml EGF. (b) Anti-phospho-EGFR Y1173 immunoblots of NIH-3T3 cell lysates treated with the indicated concentrations of BIBW2992 or erlotinib for 2 h. A representative anti-actin immunoblot is shown as a loading control.